



Re:Search

Sharing Innovation in the Fight Against Neglected Tropical Diseases

■ WIPO Re:Search – Open Innovation for NTDs

Thomas Bombelles
Head, Global Health, WIPO

April 2014

What is *WIPO Re:Search*?

- **Platform for sharing IP assets and resources** in order to catalyze research and development on NTDs, malaria, and tuberculosis
- “**Beyond Patents**”: shared IP assets and resources include pharmaceutical compounds, technologies, know-how, data, research facilities, hosting arrangements, etc.

How does it work?

- Members upload assets and resources onto the searchable, public *WIPO Re:Search* database
- Partnership Hub administrator (BVGH) actively facilitates specific collaborations between *WIPO Re:Search* Members

21 NTDs and conditions, plus malaria & TB

Buruli Ulcer	Lymphatic filariasis
Chagas disease (American trypanosomiasis)	Onchocerciasis
Cysticercosis	Rabies
Dengue/dengue hemorrhagic fever	Schistosomiasis
Dracunculiasis (guinea-worm disease)	Soil transmitted helminthiasis
Echinococcosis	Trachoma
Endemic treponematoses (Yaws)	Podoconiosis
Foodborne trematode infections	Snakebite
Human African trypanosomiasis	Malaria
Leishmaniasis	Tuberculosis
Leprosy	

WIPO's Mandate

WIPO Development Agenda (2007)

Focus on, inter alia, Technology and Knowledge Transfer, Capacity Building, and Licensing of IP to foster development in developing and LDCs.

UN Millenium Development Goals (2000) – Health-Related Objectives

Goal 4: Reduce Child Mortality

Goal 5: Improve Maternal Health

Goal 6: Combat HIV/AIDS, Malaria and Other Diseases

WIPO's “niche” is specific and targeted:

Francis Gurry, WIPO Director General: “WIPO Re:Search is a wonderful opportunity for capacity-building in R&D and innovation, sharing and creating connections which can in turn lead to the advancement of knowledge and discoveries.”

(October 2011)

Value proposition

- 1. Galvanizing industry and the public sector**
- 2. Moving the discourse to IP as a tool to foster innovation in unmet health needs**
- 3. Contributing to a “networked global health innovation system”**
- 4. Demonstrating creative open-based IP approaches within the current IP system**

Licensing Terms

- **Royalty-free to anyone in the world, for R&D and manufacture.**
- **Licenses for the sale of resulting products:**
 - royalty-free for sales in all LDCs
 - sales in other developing countries to be negotiated in good faith and based on prevalence of disease and economic development.
- **Licensees allowed to retain ownership of new IP and are encouraged to license to third parties through WIPO Re:Search**
- **No reach-through claims to new intellectual property, materials or derivatives of materials** generated by licensee, but licensor may ask for a non-assertion to such new intellectual property.

Licensing Terms

WIPO Re: Search Guiding Principles, page 3

“Providers agree to grant Users royalty-free licenses to this Intellectual Property for research and development, anywhere in the world, of products, technologies or services, for the sole purpose of addressing public health needs for any or all NTDs in LDCs. ... to make or have made such products, technologies or services, and to import and export....”

“Consider in good faith the issue of access to these products for all developing countries, ... taking into account the economic development of the countries and the need to facilitate access to disadvantaged populations.”

“Users shall be allowed to retain ownership of and apply for registration of intellectual property rights generated as they deem fit, but shall be encouraged to license to third parties through *WIPO Re:Search* new intellectual property rights generated under an agreement made pursuant to membership in the Consortium under terms consistent with these Guiding Principles.”

“For the avoidance of doubt, Providers will not make any claims to rights in new intellectual property, materials or derivatives of materials generated by a User under a license agreement made pursuant to membership in this Consortium, but may require such User not to assert such new intellectual property rights against the Provider.”

Structure

Global comprehensive database

WIPO-secretariat maintained database

Technology and related information

Publicly accessible

Partnership hub

Administered by BIO Ventures for Global Health

Connect partners
Develop relationships

Facilitate 'hosting' arrangements

Supporting services

Technical advice from WHO


Link to other WIPO Services, eg, Training, access to journals

Ongoing recruitment of new providers + users

Database content

- **Patents (incl. 1'200 families, >20'000 patents)**
- **Pre-clinical candidate compounds**
- **Screening or Hits Data**
- **Enabling technology platforms**
- **Registered/Marketed Products**
- **Hit-to-Lead Data**
- **Diagnostic Tools**
- **Other Types of Data or Services**

WIPO Re:Search Members



BIO Ventures for Global Health

Mission: Building partnerships to accelerate the development of new drugs, vaccines, and diagnostics to address the unmet medical needs of the developing world.

We have a unique perspective.



Expertise in Industry



Knowledge of Global Health

BVGH – The Partnership Hub Administrator


- Recruit new members – 80+ members
- Identify and facilitate collaborations between members – 54 agreements
- Connect members
- Increase awareness of WIPO Re:Search
 - Presentations
 - Publications
 - Newsletters
 - Media
 - Outreach

Establishing Collaborations


- BVGH proactively identifies partnership opportunities by matching contributions and resources with member's research needs
- Fields specific requests from members regarding access to IP and/or expertise
- Builds knowledge of member contributions and research programs
- Facilitates collaboration between members:
 - Organizing meetings, teleconferences
 - Facilitating ongoing communication between members and establishing mutual interest



Select WIPO Re:Search Agreements



KCCR-Stanford Collaboration



Background:

- WIPO and BVGH meet Ellis Owusu-Dabo, Scientific Director of the Kumasi Centre for Collaborative Research (KCCR) in Ghana, at the WIPO Re:Search Forum in Cape Town, April 2012
- Following a BVGH meeting at Stanford, a researcher request support in accessing stool samples from Africa containing soil transmitted helminths
- BVGH facilitated conversations between KCCR and Stanford researchers

Status:

- Agreement to share samples and publish jointly established
- Collaboration is underway



WIPO | Re:Search
Sharing Innovation
in the Fight Against
Neglected Tropical Diseases

www.wipoReSearch.org

Secretariat:
World Intellectual Property Organization
Partnership Hub Administrator:
BIO Ventures for Global Health



meet Ellis Owusu-Dabo, Scientific Director of the Kumasi Centre for Collaborative Research (KCCR), Ghana

NIH-Emory University collaboration



Background:

- BVGH presented WIPO Re:Search to Emory faculty including Dennis Liotta.
- Prof. Liotta shared his interest in accessing biology expertise for his RNA-dependent RNA polymerase inhibitor program for dengue fever.
- BVGH presented a couple of partnership options and the NIH was selected.
- BVGH connected Dennis with Christina Casseti, Dengue Program Officer, at the NIH to explore accessing biology expertise and in-kind support.

Status:

- Non-Clinical Evaluation Agreement has been established and collaboration is underway.




WIPO | Re:Search

Sharing Innovation
in the Fight Against
Neglected Tropical Diseases

www.wipoReSearch.org

Secretariat:
World Intellectual Property Organization
Partnership Hub Administration
Bio Ventures for Global Health



**meet Dr. Dennis Liotta, Professor of Chemistry at Emory University (Atlanta, Georgia)
USA**

FINANCIAL TIMES

THURSDAY OCTOBER 11 2012

Combating Neglected Diseases


A shared way forward offers hope

Research

Global co-operation may provide many of the answers, writes *Andrew Jack*

its value as an adjuvant to boost the immune response to two of its experimental vaccines, for Chagas disease and leishmaniasis.

"Adjuvants are super hard to come by because they are closely guarded by the major vaccine manufacturers," says Peter Hotez,



Research at the Novartis Institute in Singapore

Bloomberg

specialist tropical disease institute in Singapore and GlaxoSmithKline (GSK) in Spain. But a number,


them easier to take. That partly reflects the lengthy periods required for drug and vaccine testing.

Questions?

For more information:

global.challenges@wipo.int

www.wipoReSearch.org




WIPO | Re:Search
Sharing Innovation
in the Fight Against
Neglected Tropical Diseases

www.wipoReSearch.org

Secretariat:
World Intellectual Property Organization

Partnership Hub Administrator:
BIG Ventures for Global Health



Providers:
Ainyam | AstraZeneca | California Institute of Technology | Center for World Health and Medicine
Drugs for Neglected Diseases Initiative | Eisa | Fundação Oswaldo Cruz (Fiocruz) | GlaxoSmithKline |
Massachusetts Institute of Technology | Medical Research Council (South Africa) | Medicines for Malaria
Venture | MSD | National Institutes of Health (USA) | Novartis | PATH | Pfizer | Sanofi | Swiss Tropical
and Public Health Institute | University of California, Berkeley | University of Dundee (UK)